Provectus Biopharmaceuticals (PVCT) 10-Q6 Nov 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014
Document And Entity Information [Abstract]	'
Document Type	'10-Q
Amendment Flag	'false
Document Period End Date	30-Sep-14
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q3
Trading Symbol	'PVCT
Entity Registrant Name	'PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	'0000315545
Current Fiscal Year End Date	'--12-31
Entity Filer Category	'Accelerated Filer
Entity Common Stock, Shares Outstanding	180,299,739

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current Assets	'	'
Cash and cash equivalents	$17,773,680	$15,696,243
Total Current Assets	17,773,680	15,696,243
Equipment and furnishings, less accumulated depreciation of $434,479 and $429,331, respectively	95,555	30,113
Patents, net of amortization of $7,963,957 and $7,460,617, respectively	3,751,488	4,254,828
Other assets	27,000	27,000
Total Assets	21,647,723	20,008,184
Current Liabilities	'	'
Accounts payable - trade	478,200	348,869
Accrued consulting expense	91,282	61,282
Other accrued expenses	311,579	102,795
Total Current Liabilities	881,061	512,946
Warrant liability	1,227,237	12,866,572
Total Liabilities	2,108,298	13,379,518
Stockholders' Equity	'	'
Preferred stock; par value $.001 per share; 25,000,000 shares authorized; Series A 8% convertible preferred stock, 0 and 33,334 shares issued and outstanding, respectively, liquidation preference $0.75 (for 2013 in aggregate $25,001)	'	33
Common stock; par value $.001 per share; 300,000,000 authorized; 180,299,739 and 159,751,724 shares issued and outstanding, respectively	180,300	159,752
Paid-in capital	176,469,175	152,519,701
Accumulated deficit	-157,110,050	-146,050,820
Total Stockholders' Equity	19,539,425	6,628,666
Total Liabilities and Stockholders' Equity	$21,647,723	$20,008,184

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accumulated depreciation on equipment and furnishings	$434,479	$429,331
Amortization on patents	7,963,957	7,460,617
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	25,000,000	25,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	180,299,739	159,751,724
Common stock, shares outstanding	180,299,739	159,751,724
Series A 8% Convertible Preferred Stock [Member]	'	'
Preferred stock, shares issued	0	33,334
Preferred stock, shares outstanding	0	33,334
Preferred stock, liquidation preference per share	$0.75	$0.75
Aggregate liquidation preference	$25,001	$25,001
Convertible preferred stock	8.00%	8.00%

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Operating expenses	'	'	'	'
Research and development	$1,358,102	$1,296,654	$3,541,520	$2,815,519
General and administrative	2,299,799	2,185,756	8,322,312	6,864,865
Amortization	167,780	167,780	503,340	503,340
Total operating loss	-3,825,681	-3,650,190	-12,367,172	-10,183,724
Investment income	1,410	293	4,226	576
(Loss) gain on change in fair value of warrant liability	75,724	-902,798	1,303,716	-917,102
Net loss	-3,748,547	-4,552,695	-11,059,230	-11,100,250
Dividends on preferred stock	'	-38,690	'	-1,188,648
Net loss applicable to common shareholders	($3,748,547)	($4,591,385)	($11,059,230)	($12,288,898)
Basic and diluted loss per common share	($0.02)	($0.03)	($0.06)	($0.10)
Weighted average number of common shares outstanding - basic and diluted	179,088,989	131,573,656	173,729,010	126,503,388

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Unaudited) (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Paid in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2013	$6,628,666	$33	$159,752	$152,519,701	($146,050,820)
Beginning Balance, shares at Dec. 31, 2013	'	33,334	159,751,724	'	'
Issuance of stock for services	346,250	'	225	346,025	'
Issuance of stock for services, shares	'	'	225,000	'	'
Issuance of warrants for services	1,354,508	'	'	1,354,508	'
Reclassification of warrant liability	10,335,619	'	'	10,335,619	'
Cash proceeds from exercise of warrants and stock options	4,347,886	'	14,703	4,333,183	'
Cash proceeds from exercise of warrants and stock options, shares	'	'	14,703,381	'	'
Issuance of common stock and warrants pursuant to Regulation D	7,470,081	'	5,587	7,464,494	'
Issuance of preferred stock and warrants pursuant to Regulation D, shares	'	'	5,586,300	'	'
Preferred stock conversions into common stock	'	-33	33	'	'
Preferred stock conversions into common stock, shares	'	-33,334	33,334	'	'
Employee compensation from stock options	115,645	'	'	115,645	'
Net loss	-11,059,230	'	'	'	-11,059,230
Ending Balance at Sep. 30, 2014	$19,539,425	'	$180,300	$176,469,175	($157,110,050)
Ending Balance, shares at Sep. 30, 2014	'	'	180,299,739	'	'

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flow (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash Flows From Operating Activities	'	'
Net loss	($11,059,230)	($11,100,250)
Adjustments to reconcile net loss to net cash used in operating activities	'	'
Depreciation	5,148	4,650
Amortization of patents	503,340	503,340
Compensation through issuance of stock options	115,645	142,310
Issuance of stock for services	346,250	312,000
Issuance of warrants for services	1,354,508	1,527,518
Loss (gain) on change in fair value of warrant liability	-1,303,716	917,102
Change in assets and liabilities	'	'
Prepaid expenses and other current assets	'	-45,284
Accounts payable	129,331	-40,971
Accrued expenses	238,784	72,014
Net cash used in operating activities	-9,669,940	-7,707,571
Cash Flows From Investing Activities	'	'
Capital expenditures	-70,590	-6,650
Net cash used in investing activities	-70,590	-6,650
Cash Flows From Financing Activities	'	'
Net proceeds from sales of preferred stock and warrants	'	2,550,000
Net proceeds from sales of common stock and warrants	7,470,081	12,204,174
Proceeds from exercises of warrants and stock options	4,347,886	21,000
Cash paid for preferred dividends	'	-29,063
Net cash provided by financing activities	11,817,967	14,746,111
Net change in cash and cash equivalents	2,077,437	7,031,890
Cash and cash equivalents, at beginning of period	15,696,243	1,221,701
Cash and cash equivalents, at end of period	17,773,680	8,253,591
Supplemental Disclosure of Noncash Investing and Financing Activities	'	'
Reclassification of warrant liability to equity due to exercise of warrants	$10,335,619	'

Basis_of_Presentation

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	1. Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued.

Nature_of_Operations

Nature of Operations	9 Months Ended
Nature of Operations	Sep. 30, 2014
Accounting Policies [Abstract]	'
Nature of Operations	'
	2. Nature of Operations
	Provectus Biopharmaceuticals, Inc., a Delaware corporation, is a biopharmaceutical company whose planned principal operations is focusing on developing minimally invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer including melanoma, breast cancer, and cancers of the liver. To date, the Company has no revenues from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates, or sell or license the Company’s OTC products or non-core technologies.

Basic_and_Diluted_Loss_Per_Com

Basic and Diluted Loss Per Common Share	9 Months Ended
Basic and Diluted Loss Per Common Share	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Basic and Diluted Loss Per Common Share	'
	3. Basic and Diluted Loss Per Common Share
	Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options and warrants and convertible preferred stock as they are antidilutive. Potential common shares excluded from the calculation at September 30, 2014 and 2013, respectively, relate to 60,240,698 and 66,238,507 from warrants, 13,868,334 and 15,322,206 from options, and 0 and 3,705,000 from convertible preferred shares.

Equity_Transactions

Equity Transactions	9 Months Ended
Equity Transactions	Sep. 30, 2014
Text Block [Abstract]	'
Equity Transactions	'
	4. Equity Transactions
	(a) During the three months ended March 31, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $137,500. During the three months ended March 31, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $48,750.
	During the three months ended June 30, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $140,250. During the three months ended June 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $49,500.
	During the three months ended September 30, 2014, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $68,500. During the three months ended September 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $51,250.
	(b) During the three months ended March 31, 2014, the Company issued 733,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $900,317. During the three months ended March 31, 2014, 121,500 warrants were forfeited. During the three months ended March 31, 2014, 12,522,198 warrants were exercised on a cashless basis resulting in 9,100,824 common shares being issued. During the three months ended March 31, 2014, 3,036,218 warrants were exercised for $2,672,364 resulting in 3,036,218 common shares issued. During the three months ended March 31, 2013, the Company issued 1,924,973 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $409,640. During the three months ended March 31, 2013, 859,833 warrants were forfeited.
	During the three months ended June 30, 2014, the Company issued 202,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $450,002. During the three months ended June 30, 2014, 315,000 warrants were forfeited. During the three months ended June 30, 2014, 1,594,082 warrants were exercised on a cashless basis resulting in 915,467 common shares being issued. During the three months ended June 30, 2014, 372,000 warrants were exercised for $372,000 resulting in 372,000 common shares issued. During the three months ended June 30, 2013, the Company issued 2,605,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $931,655. During the three months ended June 30, 2013, 1,051,500 warrants were forfeited.

	During the three months ended September 30, 2014, the Company issued 6,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $4,189. During the three months ended September 30, 2014, 228,500 warrants were forfeited. During the three months ended September 30, 2013, the Company issued 442,000 fully vested warrants to consultants in exchange for services. Consulting costs charged to operations were $186,223. During the three months ended September 30, 2013, 136,500 warrants were forfeited.
	As the fair market value of these services was not readily determinable, these services were valued based on the fair market value of the warrants, determined using the Black-Scholes option-pricing model.
	(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $1,153,835 and $311,062, respectively. During the three months ended March 31, 2014, 858,825 of the Series A Warrants were exercised. During the three months ended March 31, 2014, 697,092 of the Series C Warrants were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $186,262 and $221,149, respectively. For the three months ended September 30, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $16,734 and $337,244, respectively. The Company determined the fair value of the Series A and Series C Warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the Series A and Series C Warrants exercised in 2014 of $3,911,370 was reclassified into additional paid-in capital.
	(d) In March and April 2010, the Company issued 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $211,422 and $446,698, respectively. During the three months ended March 31, 2014, 1,756,665 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $3,285,793 and $399,057, respectively. During the three months ended June 30, 2014, 133,232 of the warrants included in the warrant liability were exercised. For the three months ended September 30, 2014, there was a gain recognized from the revaluation of the warrant liability of $92,458. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $275,279. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $2,377,133 was reclassified into additional paid-in capital.
	(e) In February 2013, the Company issued Series A 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred stock on the consolidated statements of operations. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $921,776 and $165,750, respectively. During the three months ended March 31, 2014, 1,650,000 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $42,970 and $289,000, respectively. During the three months ended June 30, 2014, 200,000 of the warrants included in the warrant liability were exercised, which is the remainder of the 2013 warrants. For the three months ended September 30, 2013, there was a loss recognized from the revaluation of the warrant liability of $290,275. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $4,047,116 was reclassified into additional paid-in capital.

	Dividends on the Series A 8% Convertible Preferred Stock accrued at an annual rate of 8% of the original issue price and were payable in either cash or common stock. If the dividend was paid in common stock, the number of shares of common stock equaled the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends were payable quarterly on the 15th day after the quarter-end. The Company paid the dividends in common stock although was required to pay the initial dividends due in cash. The Company had a deficit and, as a result, the dividends were recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063, which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860, which are included in dividends on preferred stock on the consolidated statement of operations. At September 30, 2013, the Company recognized dividends of $28,104, which are included in dividends on preferred stock on the consolidated statement of operations. In 2014, the Company recognized no dividends because of the conversion of all outstanding preferred stock to common stock as of January 15, 2014.
	(f) In January 2014 there were 33,334 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 33,334 shares of the Company’s common stock. As of January 15, 2014, there were no shares of Series A 8% Convertible Preferred Stock outstanding.
	(g) During the three months ended June 30, 2014, the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $5,000,000. The Company accepted subscriptions, in the aggregate, for 2,000,000 shares of common stock and five year warrants to purchase 2,000,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $3.00 per share. The purchase price for each share of common stock together with the warrants was $2.50. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $650,000 and issued five year fully vested warrants to purchase 300,000 shares of common stock with an exercise price of $2.50 to Network 1 Financial Securities, Inc., which represents 15% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended September 30, 2014, the Company commenced a private offering of up to $15 million of common stock and five-year warrants to accredited investors. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants is $1.00. The Company plans to use the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. is serving as placement agent for the offering. During the three months ended September 30, 2014, the Company received subscriptions, in the aggregate, for 3,586,300 shares of common stock and five year warrants to purchase 1,793,150 shares of common stock for an aggregate of $3,586,300. Investors will receive five year fully vested warrants to purchase up to 50% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants is $1.00. The Company plans to use the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. is serving as placement agent for the offering. In connection with the offering, the Company paid $466,219 and issued five year fully vested warrants to purchase 358,630 shares of common stock with an exercise price of $1.25 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock subscribed for by investors solicited by Network 1 Financial Securities, Inc.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	5. Stock-Based Compensation
	One employee of the Company exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750, 14,248 options at an exercise price of $0.75 per share of common stock for $10,686 and 600,000 options at an exercise price of $0.93 per share of common stock for $558,000 during the three months ended March 31, 2014. Another employee of the Company exercised 300,000 options at an exercise price of $1.10 per share of common stock for $330,000 during the three months ended March 31, 2014. Another employee of the Company exercised 189,624 options at an exercise price of $1.10 per share of common stock for $208,586 during the three months ended March 31, 2014. One employee of the Company forfeited 300,000 stock options on February 26, 2014.
	One employee of the Company exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750 during the three months ended June 30, 2014. Another employee of the Company exercised 100,000 options at an exercise price of $1.25 per share of common stock for $125,000 during the three months ended June 30, 2014. A former non-employee member of the board of directors exercised 25,000 options at an exercise price of $0.95 per share of common stock for $23,750 during the three months ended June 30, 2014. One employee of the Company forfeited 25,000 stock options on May 27, 2014.
	On July 29, 2014, the Company issued a total of 150,000 stock options to its three re-elected non-employee members of the board of directors. All of the stock options issued in 2014 vested on the date of grant and have an exercise price equal to the fair market price on the date of issuance. On August 19, 2013, the Company issued a total of 250,000 stock options to its re-elected members of the board of directors. All of the stock options issued in 2013 vested on the date of grant and have an exercise price equal to the fair market price on the date of issuance.

	The compensation cost relating to stock options issued in 2014 is measured based on the fair value of the stock options issued. For purposes of estimating the fair value of each stock option on the date of grant, the Company utilized the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected volatility factor of the market price of the Company’s common stock (as determined by reviewing its historical public market closing prices). Because the Company’s employee stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee and director stock options. Included in the results of operations for both the three and nine months ended September 30, 2014 is $115,645 of stock-based compensation expense which relates to the fair value of the stock options granted during the period. Included in the results of operations for both the three and nine months ended September 30, 2013 is $142,310 of stock-based compensation expense which relates to the fair value of stock options.
	The following is a summary of nonvested stock option activity for the nine months ended September 30, 2014:


		Number of Shares			Weighted Average
					Grant-Date
					Fair Value
	Nonvested at December 31, 2013		—		$	—
	Granted		150,000		$	0.77
	Vested		(150,000	)	$	0.77
	Canceled		—			—

	Nonvested at September 30, 2014		—		$	—
	As of September 30, 2014, there was no unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the Plan.

Related_Party_Transaction

Related Party Transaction	9 Months Ended
Related Party Transaction	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transaction	'
	6. Related Party Transaction
	The Company paid one of the Company’s directors $6,000 as of March 31, 2014, all of which was paid as part of his overall compensation of an aggregate of $85,000 for board and committee service.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
Fair Value of Financial Instruments	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	7. Fair Value of Financial Instruments
	The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities.
	Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.
	Level 3: Unobservable inputs that are not corroborated by market data.
	In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are measured and reported on a fair value basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. The fair value of certain of the Company’s financial instruments, including Cash and cash equivalents and Accounts payable, approximates the carrying value due to the relatively short maturity of such instruments. The fair value of derivative instruments is determined by management with the assistance of an independent third party valuation specialist. The warrant liability is a derivative instrument and is classified as Level 3.

	The Company used the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used are as follows:


		September 30, 2014		June 30, 2014	March 31, 2014
	2010 Warrants:
	Weighted average term	0.4 years		0.7 years	0.9 years
	Probability the warrant exercise price would be reset	5%		5%	5%
	Volatility	161.80%		187.70%	66.5% to 129.7%
	Risk free interest rate	0.03%		0.09%	0.13%
	2011 Warrants:
	Weighted average term	1.3 years		1.5 years	1.8 years
	Probability the warrant exercise price would be reset	5%		5%	5%
	Volatility	144.40%		132.70%	101.80%
	Risk free interest rate	0.36%		0.29%	0.29%
	2013 Warrants:
	Weighted average term	N/A		N/A	3.9 years
	Probability the warrant exercise price would be reset	N/A		N/A	5%
	Volatility	N/A		N/A	84.70%
	Risk free interest rate	N/A		N/A	0.77% to 1.32%
	At June 30, 2014 there are no remaining 2013 warrants and therefore no associated warrant liability.
	The warrant liability measured at fair value on a recurring basis is as follows:


		Total			Level 1		Level 2		Level 3
	Derivative instruments:
	Warrant liability at September 30, 2014	$	1,227,237		$	—	$	—	$	1,227,237
	Warrant liability at December 31, 2013	$	12,866,572		$	—	$	—	$	12,866,572
	A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2014 to September 30, 2014 follows:


	Balance at January 1, 2014	$	12,866,572
	Issuance of warrants		—
	Change in fair value of warrants included in earnings		(1,303,716	)
	Reclassification to APIC due to warrant exercises		(10,335,619	)

	Balance at September 30, 2014	$	1,227,237

Litigation

Litigation	9 Months Ended
Litigation	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Litigation	'
	8. Litigation
	Kleba Shareholder Derivative Lawsuit
	On January 2, 2013, Glenn Kleba, derivatively on behalf of the Company, filed a shareholder derivative complaint in the Circuit Court for the State of Tennessee, Knox County (the “Court”), against H. Craig Dees, Timothy C. Scott, Eric A. Wachter, and Peter R. Culpepper (collectively, the “Executives”), Stuart Fuchs, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, together with the Executives, the “Individual Defendants”), and against the Company as a nominal defendant (the “Shareholder Derivative Lawsuit”). The Shareholder Derivative Lawsuit alleged (i) breach of fiduciary duties, (ii) waste of corporate assets, and (iii) unjust enrichment, all three claims based on Mr. Kleba’s allegations that the defendants authorized and/or accepted stock option awards in violation of the terms of the Company’s 2002 Stock Plan (the “Plan”) by issuing stock options in excess of the amounts authorized under the Plan and delegated to defendant H. Craig Dees the sole authority to grant himself and the other Executives cash bonuses that Mr. Kleba alleges to be excessive.
	In April 2013, the Company’s Board of Directors appointed a special litigation committee to investigate the allegations of the Shareholder Derivative Complaint and make a determination as to how the matter should be resolved. The special litigation committee conducted its investigation, and proceedings in the case were stayed pending the conclusion of the committee’s investigation. The Company has established a reserve of $100,000 for potential liabilities because such is the amount of the self-insured retention of its insurance policy. On February 21, 2014, an Amended Shareholder Derivative Complaint was filed which added Don B. Dale (“Mr. Dale”) as a plaintiff.
	On March 6, 2014, the Company filed a Joint Notice of Settlement (the “Notice of Settlement”) in the Shareholder Derivative Lawsuit. In addition to the Company, the parties to the Notice of Settlement are Mr. Kleba, Mr. Dale and the Individual Defendants.

	On June 6, 2014, the Company, in its capacity as a nominal defendant, entered into a Stipulated Settlement Agreement and Mutual Release (the “Settlement”) in the Shareholder Derivative Lawsuit. In addition to the Company and the Individual Defendants, Plaintiffs Glenn Kleba and Don B. Dale are parties to the Settlement.
	By entering into the Settlement, the settling parties have resolved the derivative claims to their mutual satisfaction. The Individual Defendants have not admitted the validity of any claims or allegations and the settling plaintiffs have not admitted that any claims or allegations lack merit or foundation. Under the terms of the Settlement, (i) the Executives each agreed (A) to re-pay to the Company $2.24 Million of the cash bonuses they each received in 2010 and 2011, which amount equals 70% of such bonuses or an estimate of the after-tax net proceeds to each Executive; provided, however, that subject to certain terms and conditions set forth in the Settlement, the Executives are entitled to a 2:1 credit such that total actual repayment may be $1.12 Million each; (B) to reimburse the Company for 25% of the actual costs, net of recovery from any other source, incurred by the Company as a result of the Shareholder Derivative Lawsuit; and (C) to grant to the Company a first priority security interest in 1,000,000 shares of the Company’s common stock owned by each such Executive to serve as collateral for the amounts due to the Company under the Settlement; (ii) Drs. Dees and Scott and Mr. Culpepper agreed to retain incentive stock options for 100,000 shares but shall forfeit 50% of the nonqualified stock options granted to each such Executive in both 2010 and 2011. The Settlement also requires that each of the Executives enter into new employment agreements with the Company, which were entered into on April 28, 2014, and that the Company adhere to certain corporate governance principles and processes in the future. Subsequent to September 30, 2014, the Executives finalized the repayment terms of the Settlement and the related options were forfeited during the fourth quarter of fiscal 2014. The cash settlement amounts will be repaid to the Company over a period of five years with the first payment due in October 2015 and the final payment due in October 2019. Under the Settlement, Messrs. Fuchs and Smith and Dr. McMasters have each agreed to pay the Company $25,000 in cash, subject to reduction by such amount that the Company’s insurance carrier pays to the Company on behalf of such defendant pursuant to such defendant’s directors and officers liability insurance policy. The Settlement also provides for an award to plaintiffs’ counsel of attorneys’ fees and reimbursement of expenses in connection with their role in this litigation, subject to Court approval.
	On July 24, 2014, the Court approved the terms of the proposed Settlement and awarded $911,000 to plaintiffs’ counsel for attorneys’ fees and reimbursement of expenses in connection with their role in the Shareholder Derivative Lawsuit. Subsequent to September 30, 2014, the Company paid $911,000 to plaintiffs’ counsel. The Company is seeking reimbursement of the full amount from insurance and if the full amount is not received from insurance, the amount remaining will be reimbursed to the Company from the Individual Defendants.
	Class Action Lawsuits
	On May 27, 2014, Cary Farrah and James H. Harrison, Jr., individually and on behalf of all others similarly situated (the “Farrah Case”), and on May 29, 2014, each of Paul Jason Chaney, individually and on behalf of all others similarly situated (the “Chaney Case”), and Jayson Dauphinee, individually and on behalf of all others similarly situated (the “Dauphinee Case”) (the plaintiffs in the Farrah Case, the Chaney Case and the Dauphinee Case collectively referred to as the “Plaintiffs”), each filed a class action lawsuit in the United States District Court for the Middle District of Tennessee against the Company, H. Craig Dees, Timothy C. Scott and Peter R. Culpepper (the “Defendants”) alleging violations by the Defendants of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. Specifically, the Plaintiffs in each of the Farrah Case, the Chaney Case and the Dauphinee Case allege that the Defendants are liable for making false statements and failing to disclose adverse facts known to them about the Company, in connection with the Company’s application to the FDA for Breakthrough Therapy Designation (“BTD”) of the Company’s melanoma drug, PV-10, in the Spring of 2014, and the FDA’s subsequent denial of the Company’s application for BTD. The Company intends to defend vigorously against all claims in these complaints. However, in view of the inherent uncertainties of litigation and the early stage of this litigation, the outcome of these cases cannot be predicted at this time. Likewise, the amount of any potential loss cannot be reasonably estimated.
	On July 9, 2014, the Plaintiffs and the Defendants filed joint motions in the Farrah Case, the Chaney Case and the Dauphinee Case to consolidate the cases and transfer them to United States District Court for the Eastern District of Tennessee. By order dated July 16, 2014, the United States District Court for the Middle District of Tennessee entered an order consolidating the Farrah Case, the Chaney Case and the Dauphinee Case (collectively and, as consolidated, the “Securities Litigation”) and transferred the Securities Litigation to the United States District Court for the Eastern District of Tennessee.
	Since the consolidation of the three actions, certain shareholders have filed motions seeking their appointment as the “Lead Plaintiff” to direct the Securities Litigation. 15 U.S.C. § 78u-4(a)(3)(B)(iii) provides a rebuttable presumption that the most adequate plaintiff to direct a securities class action is the shareholder who has the largest financial interest in the relief sought by the class. Following the motion for appointment filed by Fawwaz Hamati, a shareholder who allegedly suffered the greatest losses, all but one of the other prospective Lead Plaintiffs withdrew their request for appointment as Lead Plaintiff. However, one prospective Lead Plaintiff, shareholder Trilokie Khemai, challenged the appointment of Mr. Hamati as a Lead Plaintiff. According to Mr. Khemai, the timing of Mr. Hamati’s purchase of his stock in the Company could subject him to unique defenses not shared by the class, which would render him inadequate as the Lead Plaintiff in the Securities Litigation. A hearing is currently scheduled with the United States District Court for the Eastern District of Tennessee on November 14, 2014 to determine which shareholder should be named as Lead Plaintiff.

	Hurtado Shareholder Derivative Lawsuit
	On June 4, 2014, Karla Hurtado, derivatively on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the Middle District of Tennessee against H. Craig Dees, Timothy C. Scott, Jan E. Koe, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, the “Individual Defendants”), and against the Company as a nominal defendant (the “Hurtado Shareholder Derivative Lawsuit”). The Hurtado Shareholder Derivative Lawsuit alleges (i) breach of fiduciary duties and (ii) abuse of control, both claims based on Ms. Hurtado’s allegations that the Individual Defendants (a) recklessly permitted the Company to make false and misleading disclosures and (b) failed to implement adequate controls and procedures to ensure the accuracy of the Company’s disclosures.
	On July 25, 2014, the United States District Court for the Middle District of Tennessee entered an order transferring the case to the United States District Court for the Eastern District of Tennessee and, in light of the pending Securities Litigation, relieving the Individual Defendants from responding to the complaint in the Hurtado Shareholder Derivative Lawsuit pending further order from the United States District Court for the Eastern District of Tennessee.
	As a nominal defendant, no relief is sought against the Company itself in the Hurtado Shareholder Derivative Lawsuit.
	Montiminy Shareholder Derivative Lawsuit
	On October 24, 2014, Paul Montiminy brought a shareholder derivative complaint on behalf of the Company in the United States District Court for the Eastern District of Tennessee (the “Montiminy Shareholder Derivative Lawsuit”) against H. Craig Dees, Timothy C. Scott, Jan E. Koe, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, the “Individual Defendants”). Like the Hurtado Shareholder Derivative Lawsuit, the Montiminy Shareholder Derivative Lawsuit alleges (i) breach of fiduciary duties and (ii) gross mismanagement of the assets and business of the Company, both claims based on Mr. Montiminy’s allegations that the Individual Defendants recklessly permitted the Company to make certain false and misleading disclosures regarding the likelihood that the Company’s melanoma drug, PV-10, would qualify for BTD. As a practical matter, the factual allegations and requested relief in the Montiminy Shareholder Derivative Lawsuit are substantively the same as those in the Hurtado Shareholder Derivative Lawsuit.
	Again, as in the Hurtado Shareholder Derivative Lawsuit, no relief is sought against the Company itself; the action is against the Individual Defendants only.
	Foley Shareholder Derivative Complaint
	On October 28, 2014, Chris Foley, derivatively on behalf of the Company, filed a shareholder derivative complaint in the Chancery Court of Knox County, Tennessee against H. Craig Dees, Timothy C. Scott, Jan E. Koe, Kelly M. McMasters, and Alfred E. Smith, IV (collectively, the “Individual Defendants”), and against the Company as a nominal defendant (the “Foley Shareholder Derivative Lawsuit”). The Foley Shareholder Derivative Lawsuit was brought by the same attorney as the Montiminy Shareholder Derivative Lawsuit, Paul Kent Bramlett of Bramlett Law Offices. Other than the difference in the named plaintiff, the complaints in the Foley Shareholder Derivative Lawsuit and the Montiminy Shareholder Derivative Lawsuit are identical.

Subsequent_Event

Subsequent Event	9 Months Ended
Subsequent Event	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Event	'
	9. Subsequent Event
	On November 5, 2014, in connection with the Company’s private offering of up to $15 million of common stock and warrants to accredited investors as described in Note 4(g), the Company accepted subscriptions, in the aggregate, for 3,702,600 shares of common stock and five year warrants to purchase 1,851,300 shares of common stock. Investors received five year fully vested warrants to purchase up to 50% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants was $1.00. As of September 30, 2014, gross proceeds of $3,586,300 have been received. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $370,260 and issued five year fully vested warrants to purchase 370,260 shares of common stock with an exercise price of $1.25 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. The issuances of the securities were exempt from the registration requirements of the Securities Act of 1933 (the “Securities Act”) by virtue of Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.

Equity_Transactions_Policies

Equity Transactions (Policies)	9 Months Ended
Equity Transactions (Policies)	Sep. 30, 2014
Text Block [Abstract]	'
Derivatives Policies	'
	(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $1,153,835 and $311,062, respectively. During the three months ended March 31, 2014, 858,825 of the Series A Warrants were exercised. During the three months ended March 31, 2014, 697,092 of the Series C Warrants were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $186,262 and $221,149, respectively. For the three months ended September 30, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $16,734 and $337,244, respectively. The Company determined the fair value of the Series A and Series C Warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the Series A and Series C Warrants exercised in 2014 of $3,911,370 was reclassified into additional paid-in capital.
	(d) In March and April 2010, the Company issued 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $211,422 and $446,698, respectively. During the three months ended March 31, 2014, 1,756,665 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $3,285,793 and $399,057, respectively. During the three months ended June 30, 2014, 133,232 of the warrants included in the warrant liability were exercised. For the three months ended September 30, 2014, there was a gain recognized from the revaluation of the warrant liability of $92,458. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $275,279. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $2,377,133 was reclassified into additional paid-in capital.
	(e) In February 2013, the Company issued Series A 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred stock on the consolidated statements of operations. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2014 and 2013, there was a loss recognized from the revaluation of the warrant liability of $921,776 and $165,750, respectively. During the three months ended March 31, 2014, 1,650,000 of the warrants included in the warrant liability were exercised. For the three months ended June 30, 2014 and 2013, there was a gain recognized from the revaluation of the warrant liability of $42,970 and $289,000, respectively. During the three months ended June 30, 2014, 200,000 of the warrants included in the warrant liability were exercised, which is the remainder of the 2013 warrants. For the three months ended September 30, 2013, there was a loss recognized from the revaluation of the warrant liability of $290,275. The Company determined the fair value of the warrants exercised on the date of exercise and adjusted the related warrant liability accordingly. The adjusted fair value of the warrants exercised in 2014 of $4,047,116 was reclassified into additional paid-in capital.

	Dividends on the Series A 8% Convertible Preferred Stock accrued at an annual rate of 8% of the original issue price and were payable in either cash or common stock. If the dividend was paid in common stock, the number of shares of common stock equaled the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends were payable quarterly on the 15th day after the quarter-end. The Company paid the dividends in common stock although was required to pay the initial dividends due in cash. The Company had a deficit and, as a result, the dividends were recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063, which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860, which are included in dividends on preferred stock on the consolidated statement of operations. At September 30, 2013, the Company recognized dividends of $28,104, which are included in dividends on preferred stock on the consolidated statement of operations. In 2014, the Company recognized no dividends because of the conversion of all outstanding preferred stock to common stock as of January 15, 2014.
	(f) In January 2014 there were 33,334 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 33,334 shares of the Company’s common stock. As of January 15, 2014, there were no shares of Series A 8% Convertible Preferred Stock outstanding.
	(g) During the three months ended June 30, 2014, the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $5,000,000. The Company accepted subscriptions, in the aggregate, for 2,000,000 shares of common stock and five year warrants to purchase 2,000,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $3.00 per share. The purchase price for each share of common stock together with the warrants was $2.50. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $650,000 and issued five year fully vested warrants to purchase 300,000 shares of common stock with an exercise price of $2.50 to Network 1 Financial Securities, Inc., which represents 15% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc. During the three months ended September 30, 2014, the Company commenced a private offering of up to $15 million of common stock and five-year warrants to accredited investors. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants is $1.00. The Company plans to use the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. is serving as placement agent for the offering. During the three months ended September 30, 2014, the Company received subscriptions, in the aggregate, for 3,586,300 shares of common stock and five year warrants to purchase 1,793,150 shares of common stock for an aggregate of $3,586,300. Investors will receive five year fully vested warrants to purchase up to 50% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.25 per share. The purchase price for each share of common stock together with the warrants is $1.00. The Company plans to use the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. is serving as placement agent for the offering. In connection with the offering, the Company paid $466,219 and issued five year fully vested warrants to purchase 358,630 shares of common stock with an exercise price of $1.25 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock subscribed for by investors solicited by Network 1 Financial Securities, Inc.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
Stock-Based Compensation (Tables)	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of Nonvested Stock Option Activity	'
	The following is a summary of nonvested stock option activity for the nine months ended September 30, 2014:


		Number of Shares			Weighted Average
					Grant-Date
					Fair Value
	Nonvested at December 31, 2013		—		$	—
	Granted		150,000		$	0.77
	Vested		(150,000	)	$	0.77
	Canceled		—			—

	Nonvested at September 30, 2014		—		$	—

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
Fair Value of Financial Instruments (Tables)	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Estimated Fair Value of Warrants	'
	The Company used the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used are as follows:


		September 30, 2014		June 30, 2014	March 31, 2014
	2010 Warrants:
	Weighted average term	0.4 years		0.7 years	0.9 years
	Probability the warrant exercise price would be reset	5%		5%	5%
	Volatility	161.80%		187.70%	66.5% to 129.7%
	Risk free interest rate	0.03%		0.09%	0.13%
	2011 Warrants:
	Weighted average term	1.3 years		1.5 years	1.8 years
	Probability the warrant exercise price would be reset	5%		5%	5%
	Volatility	144.40%		132.70%	101.80%
	Risk free interest rate	0.36%		0.29%	0.29%
	2013 Warrants:
	Weighted average term	N/A		N/A	3.9 years
	Probability the warrant exercise price would be reset	N/A		N/A	5%
	Volatility	N/A		N/A	84.70%
	Risk free interest rate	N/A		N/A	0.77% to 1.32%
Warrant Liability Measured at Fair Value on a Recurring Basis	'
	The warrant liability measured at fair value on a recurring basis is as follows:


		Total			Level 1		Level 2		Level 3
	Derivative instruments:
	Warrant liability at September 30, 2014	$	1,227,237		$	—	$	—	$	1,227,237
	Warrant liability at December 31, 2013	$	12,866,572		$	—	$	—	$	12,866,572
Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis	'
	A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2014 to September 30, 2014 follows:


	Balance at January 1, 2014	$	12,866,572
	Issuance of warrants		—
	Change in fair value of warrants included in earnings		(1,303,716	)
	Reclassification to APIC due to warrant exercises		(10,335,619	)

	Balance at September 30, 2014	$	1,227,237

Nature_of_Operations_Additiona

Nature of Operations - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Revenues from planned principal operations	$0

Basic_and_Diluted_Loss_Per_Com1

Basic and Diluted Loss Per Common Share - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Common shares excluded from the calculation	60,240,698	66,238,507
Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Common shares excluded from the calculation	13,868,334	15,322,206
8% Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Common shares excluded from the calculation	0	3,705,000

Equity_Transactions_Additional

Equity Transactions - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

3 Months Ended

Jan. 15, 2014

Jan. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Apr. 30, 2010

Mar. 31, 2010

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2014

Feb. 28, 2014

Jun. 30, 2014

Mar. 31, 2014

Mar. 31, 2013

Jun. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Jun. 30, 2014

Mar. 31, 2014

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Network 1 Financial Securities [Member]

Series A Warrants [Member]

Series C Warrants [Member]

Series A and Series C Warrants [Member]

Five Year Warrant [Member]

Common Stock [Member]

8% Convertible Preferred Stock [Member]

Warrants [Member]

Series A 8% Convertible Preferred Stock [Member]

Warrant A [Member]

Network 1 Financial Securities [Member]

Class of Stock [Line Items]

Issuance of common stock to consultants

75,000

Consulting costs charges

$68,500

$140,250

$137,500

$51,250

$49,500

$48,750

Issuance of warrants to consultants

6,000

202,000

733,000

442,000

2,605,000

1,924,973

Consulting costs charges related to warrants

4,189

450,002

900,317

186,223

931,655

409,640

Warrants forfeited

228,500

315,000

121,500

136,500

1,051,500

859,833

Warrants exercised on cashless basis

1,594,082

12,522,198

Shares issued in cashless exercise

915,467

9,100,824

Warrants exercised

372,000

3,036,218

Exercise price of warrants

372,000

2,672,364

Common stock to be issued on exercise of warrant

372,000

3,036,218

358,630

300,000

370,260

Gain (loss) on revaluation of warrants liability

-16,734

186,262

-1,153,835

-337,244

221,149

-311,062

92,458

3,285,793

-211,422

-275,279

399,057

-446,698

42,970

-921,776

-290,275

289,000

-165,750

Warrants series exercised

858,825

697,092

Adjusted fair value of warrants exercised

3,911,370

2,377,133

4,047,116

Convertible preferred stock

8.00%

Issued warrants

133,232

1,756,665

200,000

1,650,000

Fair value of the warrants

1,297,950

Beneficial conversion amount

1,025,950

Dividends on preferred stock

38,690

1,188,648

29,063

50,860

28,104

Converted preferred stock

33,334

Preferred stock converted into shares

33,334

Gross proceeds from private offering of common stock and warrants to accredited investors

5,000,000

15,000,000

Company accepted subscriptions in aggregate

3,586,300

2,000,000

Expiration of warrants

'5 years

Number of shares issuable on exercises of warrants issued

1,793,150

2,000,000

Investors received five year warrants

50.00%

100.00%

Exercise price of common stock

$1.25

$2.50

$1.25

Purchase price of common stock with warrants

$2.50

Payment of fully vested warrants

370,260

466,219

650,000

Percentage of total number of shares of common stock sold to investors

10.00%

15.00%

Aggregate amount of common stock

$3,586,300

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

Jul. 29, 2014

Feb. 26, 2014

Aug. 19, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

27-May-14

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Mar. 31, 2014

Jul. 29, 2014

Employee One [Member]

Options Exercised Price One [Member]

Options Exercised Price Two [Member]

Options Exercised Price Three [Member]

Non Employee Directors [Member]

Employee One [Member]

Employee Two [Member]

Employee Three [Member]

Non Employee [Member]

Employee One [Member]

Directors

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options exercised at an exercise price

25,000

300,000

100,000

189,624

25,000

14,248

600,000

Exercise price/share

$0.95

$1.10

$1.25

$1.10

$0.95

$0.75

$0.93

Common stock value

$23,750

$330,000

$125,000

$208,586

$23,750

$10,686

$558,000

Number of Shares forfeited

300,000

25,000

Number of stock option issued

150,000

250,000

150,000

Number of re-elected non-employee members of the board of directors

Stock-based compensation expense

115,645

142,310

115,645

142,310

Unrecognized stock-based compensation expense

Stock_Based_Compensation_Summa

Stock Based Compensation - Summary of Nonvested Stock Option Activity (Detail) (USD $)	0 Months Ended		9 Months Ended
	Jul. 29, 2014	Aug. 19, 2013	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'
Nonvested, Beginning balance, Number of Shares	'	'	'
Granted, Number of Shares	150,000	250,000	150,000
Vested, Number of Shares	'	'	-150,000
Canceled, Number of Shares	'	'	'
Nonvested, Ending balance, Number of Shares	'	'	'
Nonvested, beginning balance, Weighted Average Grant-Date Fair Value	'	'	'
Granted, Weighted Average Grant-Date Fair Value	'	'	$0.77
Vested, Weighted Average Grant-Date Fair Value	'	'	$0.77
Canceled, Weighted Average Grant-Date Fair Value	'	'	'
Nonvested, Outstanding, Ending balance, Weighted Average Grant-Date Fair Value	'	'	'

Related_Party_Transaction_Addi

Related Party Transaction - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended
	Mar. 31, 2014	Sep. 30, 2014
	Mar. 31, 2014	Directors
Related Party Transactions [Abstract]	'	'
Payment for board and committee service	$6,000	$85,000
Number of directors to whom board and committee service paid	'	1

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Estimated Fair Value of Warrants (Detail)	3 Months Ended	6 Months Ended	9 Months Ended
	Mar. 31, 2014	Jun. 30, 2014	Sep. 30, 2014
2010 Warrants [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Weighted average term	'10 months 24 days	'8 months 12 days	'4 months 24 days
Probability the warrant exercise price would be reset	5.00%	5.00%	5.00%
Volatility	'	187.70%	161.80%
Risk free interest rate	0.13%	0.09%	0.03%
2010 Warrants [Member] \| Minimum [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Volatility	66.50%	'	'
2010 Warrants [Member] \| Maximum [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Volatility	129.70%	'	'
2011 Warrants [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Weighted average term	'1 year 9 months 18 days	'1 year 6 months	'1 year 3 months 18 days
Probability the warrant exercise price would be reset	5.00%	5.00%	5.00%
Volatility	101.80%	132.70%	144.40%
Risk free interest rate	0.29%	0.29%	0.36%
2013 Warrants [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Weighted average term	'3 years 10 months 24 days	'	'
Probability the warrant exercise price would be reset	5.00%	'	'
Volatility	84.70%	'	'
2013 Warrants [Member] \| Minimum [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Risk free interest rate	0.77%	'	'
2013 Warrants [Member] \| Maximum [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Risk free interest rate	1.32%	'	'

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Warrant Liability Measured at Fair Value on a Recurring Basis (Detail) (Recurring [Member], Warrants [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	$1,227,237	$12,866,572
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	'	'
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	'	'
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	$1,227,237	$12,866,572

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Reclassification to APIC due to warrant exercises	$10,335,619
Recurring [Member] \| Level 3 [Member] \| Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Beginning Balance	12,866,572
Issuance of warrants	'
Change in fair value of warrants included in earnings	-1,303,716
Reclassification to APIC due to warrant exercises	-10,335,619
Ending Balance	$1,227,237

Litigation_Additional_Informat

Litigation - Additional Information (Detail) (USD $)	0 Months Ended		9 Months Ended
Litigation - Additional Information (Detail) (USD $)	Jul. 24, 2014	Jun. 06, 2014	Sep. 30, 2014	Apr. 30, 2013
Loss Contingencies [Line Items]	'	'	'	'
Reserve for litigation	'	'	'	$100,000
Damages sought to be receivable	'	2,240,000	'	'
Estimated bonus percentage	'	70.00%	'	'
Future payment ratio of contingent consideration	'	2	'	'
Repayment under contingency	'	1,120,000	'	'
Reimbursement cost percentage	'	25.00%	'	'
Attorney's fees and reimbursement of expenses	911,000	'	'	'
Cash settlement repayment period	'	'	'5 years	'
Payment to plaintiff's counsel	'	'	911,000	'
Executive Officer [Member]	'	'	'	'
Loss Contingencies [Line Items]	'	'	'	'
Number of shares acquired under litigation	'	1,000,000	'	'
Stock option issued to employees	'	100,000	'	'
Share-based compensation forfeiture rate	'	50.00%	'	'
Other Defendants [Member]	'	'	'	'
Loss Contingencies [Line Items]	'	'	'	'
Damages sought to be receivable	'	$25,000	'	'

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (USD $)

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Nov. 05, 2014

Network 1 Financial Securities [Member]

Five Year Warrant [Member]

Subsequent Event [Member]

Network 1 Financial Securities [Member]

Five Year Warrant [Member]

Subsequent Event [Line Items]

Gross proceeds from private offering of common stock and warrants to accredited investors

$5,000,000

$15,000,000

$3,702,600

Number of shares issuable on exercises of warrants issued

1,793,150

2,000,000

1,851,300

Expiration of warrants

'5 years

Investors received five year warrants

50.00%

100.00%

50.00%

Exercise price of common stock

$1.25

$2.50

$1.25

Purchase price of common stock with warrants

$2.50

Common stock to be issued on exercise of warrant

372,000

3,036,218

358,630

300,000

370,260

Percentage of total number of shares of common stock sold to investors

10.00%

15.00%

Payment of fully vested warrants

370,260

466,219

650,000

Gross proceeds on issuance of warrants

$3,586,300